These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 25092912

  • 1. Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites.
    Mizutani M, Iyori M, Blagborough AM, Fukumoto S, Funatsu T, Sinden RE, Yoshida S.
    Infect Immun; 2014 Oct; 82(10):4348-57. PubMed ID: 25092912
    [Abstract] [Full Text] [Related]

  • 2. A two-dose viral-vectored Plasmodium vivax multistage vaccine confers durable protection and transmission-blockade in a pre-clinical study.
    Yamamoto Y, Fabbri C, Okuhara D, Takagi R, Kawabata Y, Katayama T, Iyori M, Hasyim AA, Sakamoto A, Mizukami H, Shida H, Lopes S, Yoshida S.
    Front Immunol; 2024 Oct; 15():1372584. PubMed ID: 38745665
    [Abstract] [Full Text] [Related]

  • 3. A Multi-Stage Plasmodium vivax Malaria Vaccine Candidate Able to Induce Long-Lived Antibody Responses Against Blood Stage Parasites and Robust Transmission-Blocking Activity.
    McCaffery JN, Fonseca JA, Singh B, Cabrera-Mora M, Bohannon C, Jacob J, Arévalo-Herrera M, Moreno A.
    Front Cell Infect Microbiol; 2019 Oct; 9():135. PubMed ID: 31119106
    [Abstract] [Full Text] [Related]

  • 4. Development of a Plasmodium berghei transgenic parasite expressing the full-length Plasmodium vivax circumsporozoite VK247 protein for testing vaccine efficacy in a murine model.
    Mizutani M, Fukumoto S, Soubeiga AP, Soga A, Iyori M, Yoshida S.
    Malar J; 2016 Apr 30; 15(1):251. PubMed ID: 27129682
    [Abstract] [Full Text] [Related]

  • 5. Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors.
    Atcheson E, Bauza K, Salman AM, Alves E, Blight J, Viveros-Sandoval ME, Janse CJ, Khan SM, Hill AVS, Reyes-Sandoval A.
    Infect Immun; 2018 Sep 30; 86(9):. PubMed ID: 29986894
    [Abstract] [Full Text] [Related]

  • 6. A Viral-Vectored Multi-Stage Malaria Vaccine Regimen With Protective and Transmission-Blocking Efficacies.
    Yusuf Y, Yoshii T, Iyori M, Mizukami H, Fukumoto S, Yamamoto DS, Emran TB, Amelia F, Islam A, Syafira I, Yoshida S.
    Front Immunol; 2019 Sep 30; 10():2412. PubMed ID: 31681301
    [Abstract] [Full Text] [Related]

  • 7. A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles.
    Gimenez AM, Salman AM, Marques RF, López-Camacho C, Harrison K, Kim YC, Janse CJ, Soares IS, Reyes-Sandoval A.
    Sci Rep; 2021 Sep 09; 11(1):17928. PubMed ID: 34504134
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of combination vaccines targeting transmission of Plasmodium falciparum and P. vivax.
    Cao Y, Hayashi CTH, Araujo MDS, Tripathi AK, Andrade AO, Medeiros JF, Vinetz J, Kumar N.
    Vaccine; 2024 Aug 30; 42(21):126140. PubMed ID: 39033079
    [Abstract] [Full Text] [Related]

  • 9. Antibodies to Plasmodium vivax transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 do not show synergism.
    Hisaeda H, Collins WE, Saul A, Stowers AW.
    Vaccine; 2001 Dec 12; 20(5-6):763-70. PubMed ID: 11738740
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites.
    Bauza K, Malinauskas T, Pfander C, Anar B, Jones EY, Billker O, Hill AV, Reyes-Sandoval A.
    Infect Immun; 2014 Mar 12; 82(3):1277-86. PubMed ID: 24379295
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Immunogenicity and transmission-blocking potential of quiescin sulfhydryl oxidase in Plasmodium vivax.
    Zheng W, Cheng S, Liu F, Yu X, Zhao Y, Yang F, Thongpoon S, Roobsoong W, Sattabongkot J, Luo E, Cui L, Cao Y.
    Front Cell Infect Microbiol; 2024 Mar 12; 14():1451063. PubMed ID: 39258252
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evaluation of transmission-blocking potential of PvPSOP25 using transgenic murine malaria parasite and clinical isolates.
    Zhang B, Feng H, Zhao Y, Zhang D, Yu X, Li Y, Zeng Y, Thongpoon S, Roobsoong W, Wu Y, Liu F, Sattabongkot J, Min H, Cui L, Cao Y.
    PLoS Negl Trop Dis; 2024 Jun 12; 18(6):e0012231. PubMed ID: 38865344
    [Abstract] [Full Text] [Related]

  • 17. Tricomponent immunopotentiating system as a novel molecular design strategy for malaria vaccine development.
    Miyata T, Harakuni T, Tsuboi T, Sattabongkot J, Ikehara A, Tachibana M, Torii M, Matsuzaki G, Arakawa T.
    Infect Immun; 2011 Oct 12; 79(10):4260-75. PubMed ID: 21807905
    [Abstract] [Full Text] [Related]

  • 18. A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses.
    Jones RM, Chichester JA, Manceva S, Gibbs SK, Musiychuk K, Shamloul M, Norikane J, Streatfield SJ, van de Vegte-Bolmer M, Roeffen W, Sauerwein RW, Yusibov V.
    Hum Vaccin Immunother; 2015 Oct 12; 11(1):124-32. PubMed ID: 25483525
    [Abstract] [Full Text] [Related]

  • 19. The Plasmodium berghei sexual stage antigen PSOP12 induces anti-malarial transmission blocking immunity both in vivo and in vitro.
    Sala KA, Nishiura H, Upton LM, Zakutansky SE, Delves MJ, Iyori M, Mizutani M, Sinden RE, Yoshida S, Blagborough AM.
    Vaccine; 2015 Jan 09; 33(3):437-45. PubMed ID: 25454088
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.